Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: April 03, 2024
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.
Journal: The Lancet. Infectious diseases
Published: March 08, 2024
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection.
Journal: Open forum infectious diseases
Published: September 19, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
Journal: Research square
Published: July 03, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
Journal: Nature communications
Published: May 16, 2023
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials.
Journal: JAMA network open
Published: January 23, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.
Journal: Nature communications
Published: January 11, 2023
Forty years of investment in HIV research: progress towards ending the HIV pandemic and preparation for future pandemics.
Journal: Journal of the International AIDS Society
Published: October 27, 2022
Optimizing the Immunogenicity of HIV Vaccines by Adjuvants - NIAID Workshop Report.
Journal: Vaccine
Published: October 13, 2022
The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.
Journal: Science translational medicine
Published: June 09, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Infectious diseases
Published: April 04, 2022
Leveraging lessons learned from the COVID-19 pandemic for HIV.
Journal: Communications medicine
Published: February 23, 2022
Last Updated: 09/26/2026